An experimental blood pressure pill called lorundrostat lowered both blood pressure and a key marker of kidney damage in people with chronic kidney disease, according to trial data presented at the American Society of Nephrology's Kidney Week in Denver. The results come from a subgroup analysis of the Phase 3 Launch-HTN trial, which was sponsored by the drug's developer, Mineralys Therapeutics. The FDA is reviewing the drug for high blood pressure, with a target action date of Dec. 22.
The findings matter because high blood pressure and kidney disease feed each other. About 14 percent of U.S. adults, or roughly 37 million people, have chronic kidney disease, and about 21 percent of adults with high blood pressure have it too, according to the CDC. Many of these patients already take several blood pressure drugs and still miss their targets.
